- In late May 2026, Precigen reported updated long-term follow-up data showing sustained complete responses and no new safety issues for PAPZIMEOS, which had already received full FDA approval and seven-year US market exclusivity as the first and only therapy for adults with recurrent respiratory papillomatosis.
- The durability of response, with most complete responders remaining surgery-free for at least three years and some beyond four years, underlines PAPZIMEOS’s role as a new immunotherapy option that targets the root viral cause of the disease.
- We’ll now examine how this long-term durability data for PAPZIMEOS may influence Precigen’s investment narrative and longer-term revenue expectations.
Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
Precigen Investment Narrative Recap
To own Precigen, you need to believe PAPZIMEOS can support a sustainable, growing business as the first and only approved therapy for adult RRP, while the company moves toward profitability from a small revenue base and high fixed costs. The latest long term data, showing durable complete responses without new safety issues, supports the core thesis that PAPZIMEOS can remain a surgery sparing standard, but it does not remove execution risk around uptake, pricing, and cash runway in the next 12 to 24 months.
The most relevant recent event alongside the durability update is Precigen’s Q1 2026 report, which showed revenue of US$23.25 million against a net loss of US$7.93 million, underscoring how dependent the path to breakeven still is on PAPZIMEOS uptake and cost control. For me, pairing the encouraging long term outcomes with these still modest financials highlights the tension between a clinically strong asset and a balance sheet that offers limited margin for operational missteps.
Yet investors should also be aware that if PAPZIMEOS real world usage falls short of expectations, high commercial and manufacturing costs could...
Read the full narrative on Precigen (it's free!)
Precigen's narrative projects $299.5 million revenue and $118.4 million earnings by 2028. This requires 262.1% yearly revenue growth and a $544.3 million earnings increase from $-425.9 million today.
Uncover how Precigen's forecasts yield a $8.50 fair value, a 137% upside to its current price.
Exploring Other Perspectives
Nine members of the Simply Wall St Community see fair value anywhere from US$0.52 to US$23.71 per share, reflecting sharply different expectations. As you weigh those views against the new durability data for PAPZIMEOS and the company’s tight cash runway, it is worth exploring how each perspective treats the risk that uptake might not scale fast enough to cover fixed costs.
Explore 9 other fair value estimates on Precigen - why the stock might be worth less than half the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Precigen research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
- Our free Precigen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Precigen's overall financial health at a glance.
Interested In Other Possibilities?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
- AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com